Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

With so many options available for addressing the disease, it shouldn’t be accepted as inevitable, a scientific statement ...

Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

Yet 44% of the high-risk patients, from LAAO’s early era, died by 5 years—researchers say this knowledge can aid ...

New US hypertension guidelines, the first since 2017, released today reinforce prior recommendations that prioritize lowering ...

Effects are more modest in placebo-controlled versus nonrandomized studies, with experts calling for further research.

The findings are encouraging but likely don’t apply to countries with ready access to thrombectomy, one expert says.

Japanese registry data point to fewer deaths and heart failure hospitalizations, especially when MR is reduced to mild or ...

The advantage over balloon angioplasty in this higher-risk subset was consistent with the results seen in single-layer ISR.

The study can’t supplant an RCT in this space, but does provide clear support for both short DAPT and P2Y12 inhibitors ...

In-store opportunities for patients to check in with their health may offer touchpoints to those who don’t regularly seek ...